Aura Biosciences (AURA) Competitors $9.14 -0.17 (-1.83%) (As of 12/2/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends AURA vs. GLPG, ARVN, NAMS, EVO, IMCR, KNSA, NTLA, OCUL, TVTX, and NRIXShould you be buying Aura Biosciences stock or one of its competitors? The main competitors of Aura Biosciences include Galapagos (GLPG), Arvinas (ARVN), NewAmsterdam Pharma (NAMS), Evotec (EVO), Immunocore (IMCR), Kiniksa Pharmaceuticals (KNSA), Intellia Therapeutics (NTLA), Ocular Therapeutix (OCUL), Travere Therapeutics (TVTX), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry. Aura Biosciences vs. Galapagos Arvinas NewAmsterdam Pharma Evotec Immunocore Kiniksa Pharmaceuticals Intellia Therapeutics Ocular Therapeutix Travere Therapeutics Nurix Therapeutics Aura Biosciences (NASDAQ:AURA) and Galapagos (NASDAQ:GLPG) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, community ranking, valuation, dividends and media sentiment. Do analysts rate AURA or GLPG? Aura Biosciences presently has a consensus price target of $23.00, indicating a potential upside of 151.64%. Galapagos has a consensus price target of $30.75, indicating a potential upside of 9.86%. Given Aura Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Aura Biosciences is more favorable than Galapagos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aura Biosciences 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Galapagos 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71 Which has stronger valuation & earnings, AURA or GLPG? Galapagos has higher revenue and earnings than Aura Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAura BiosciencesN/AN/A-$76.41M-$1.73-5.28Galapagos$259.40M7.11$229.12MN/AN/A Do institutionals and insiders hold more shares of AURA or GLPG? 96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 32.5% of Galapagos shares are owned by institutional investors. 5.4% of Aura Biosciences shares are owned by insiders. Comparatively, 2.9% of Galapagos shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media refer more to AURA or GLPG? In the previous week, Aura Biosciences had 4 more articles in the media than Galapagos. MarketBeat recorded 6 mentions for Aura Biosciences and 2 mentions for Galapagos. Aura Biosciences' average media sentiment score of 0.68 beat Galapagos' score of 0.43 indicating that Aura Biosciences is being referred to more favorably in the media. Company Overall Sentiment Aura Biosciences Positive Galapagos Neutral Which has more volatility & risk, AURA or GLPG? Aura Biosciences has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Is AURA or GLPG more profitable? Galapagos' return on equity of 0.00% beat Aura Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Aura BiosciencesN/A -41.57% -36.43% Galapagos N/A N/A N/A Does the MarketBeat Community favor AURA or GLPG? Galapagos received 443 more outperform votes than Aura Biosciences when rated by MarketBeat users. Likewise, 64.10% of users gave Galapagos an outperform vote while only 62.16% of users gave Aura Biosciences an outperform vote. CompanyUnderperformOutperformAura BiosciencesOutperform Votes2362.16% Underperform Votes1437.84% GalapagosOutperform Votes46664.10% Underperform Votes26135.90% SummaryAura Biosciences beats Galapagos on 9 of the 15 factors compared between the two stocks. Ad Chaikin AnalyticsBofA is watching for a market topU.S. tech stocks have soared so high for so long that they're no longer just minting new millionaires... They're minting new billionaires. The number of American billionaires has skyrocketed over last year – their wealth hitting a record $12.1 trillion – thanks to the Nasdaq's extraordinary outperformance. But now, after two years of near-vertical gains...New warnings out of Wall Street suggest that the winds are about to change. Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AURA vs. The Competition Export to ExcelMetricAura BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$456.55M$3.05B$5.31B$8.94BDividend YieldN/A1.84%5.23%4.05%P/E Ratio-5.2847.13136.9718.02Price / SalesN/A489.601,455.46155.72Price / CashN/A175.8441.6738.60Price / Book2.614.967.336.66Net Income-$76.41M-$41.68M$117.74M$224.93M7 Day Performance2.01%10.83%3.38%2.50%1 Month Performance-9.95%11.26%2.50%10.23%1 Year Performance11.74%38.03%35.96%30.14% Aura Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AURAAura Biosciences3.8527 of 5 stars$9.14-1.8%$23.00+151.6%+11.7%$465.05MN/A-5.2850Short Interest ↓News CoveragePositive NewsGLPGGalapagos0.3433 of 5 stars$27.83+0.7%$30.75+10.5%-26.0%$1.83B$259.40M0.001,123Short Interest ↑ARVNArvinas2.7148 of 5 stars$26.43-1.1%$61.08+131.1%+9.0%$1.82B$78.50M-5.72445Gap DownNAMSNewAmsterdam Pharma3.0895 of 5 stars$19.41-2.2%$33.80+74.1%+102.7%$1.79B$14.09M0.0057EVOEvotec1.7588 of 5 stars$4.64-1.1%$5.93+27.9%-52.6%$1.64B$777.05M0.005,061IMCRImmunocore2.7373 of 5 stars$32.64-0.3%$69.18+112.0%-38.3%$1.63B$296.31M-34.46497Positive NewsKNSAKiniksa Pharmaceuticals2.8442 of 5 stars$22.00-0.4%$36.60+66.4%+30.0%$1.59B$384.10M-157.29220News CoveragePositive NewsNTLAIntellia Therapeutics4.2783 of 5 stars$15.55-0.4%$54.94+253.3%-49.0%$1.58B$36.28M-2.87600OCULOcular Therapeutix4.0699 of 5 stars$9.93+0.4%$16.71+68.3%+264.6%$1.56B$58.44M-7.49267TVTXTravere Therapeutics2.5267 of 5 stars$19.61+4.3%$22.62+15.3%+204.8%$1.53B$203.45M-4.27460NRIXNurix Therapeutics2.8191 of 5 stars$21.54-2.6%$29.40+36.5%+211.0%$1.53B$56.42M-7.60300Positive NewsGap Up Related Companies and Tools Related Companies Galapagos Competitors Arvinas Competitors NewAmsterdam Pharma Competitors Evotec Competitors Immunocore Competitors Kiniksa Pharmaceuticals Competitors Intellia Therapeutics Competitors Ocular Therapeutix Competitors Travere Therapeutics Competitors Nurix Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AURA) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
